The early effect of dapagliflozin on diastolic function parameters in patients with mid range and reduced ejection fraction heart failure
Mohamed, A., Eldarky, E., Ateya, A., Allam, H. (2024). The early effect of dapagliflozin on diastolic function parameters in patients with mid range and reduced ejection fraction heart failure. EKB Journal Management System, 9(12), 1-4. doi: 10.21608/bjas.2024.340860.1541
Ahmed Abdel Aziz Mohamed; Elsayyed Abdelkhalek Eldarky; Ali Ibrahim Ateya; Hagar Ibrahim Allam. "The early effect of dapagliflozin on diastolic function parameters in patients with mid range and reduced ejection fraction heart failure". EKB Journal Management System, 9, 12, 2024, 1-4. doi: 10.21608/bjas.2024.340860.1541
Mohamed, A., Eldarky, E., Ateya, A., Allam, H. (2024). 'The early effect of dapagliflozin on diastolic function parameters in patients with mid range and reduced ejection fraction heart failure', EKB Journal Management System, 9(12), pp. 1-4. doi: 10.21608/bjas.2024.340860.1541
Mohamed, A., Eldarky, E., Ateya, A., Allam, H. The early effect of dapagliflozin on diastolic function parameters in patients with mid range and reduced ejection fraction heart failure. EKB Journal Management System, 2024; 9(12): 1-4. doi: 10.21608/bjas.2024.340860.1541

The early effect of dapagliflozin on diastolic function parameters in patients with mid range and reduced ejection fraction heart failure

Benha Journal of Applied Sciences
Article 1, Volume 9, Issue 12, December 2024, Page 1-4  XML PDF (273.66 K)
Document Type: Original Research Papers
DOI: 10.21608/bjas.2024.340860.1541
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Abdel Aziz Mohamed email 1; Elsayyed Abdelkhalek Eldarky2; Ali Ibrahim Ateya3; Hagar Ibrahim Allam4
1Cardiology Dept., Faculty of Medicine, Benha Univ., Benha, Egypt
2Professor of Cardiology Faculty of Medicine – Benha University
3Assistant Professor of Cardiology Faculty of Medicine – Benha University
4Lecturer of Cardiology Faculty of Medicine – Benha University
Abstract
Cardiovascular mortality and hospitalisation rates were greatest among heart failure (HF) patients with reduced ejection fraction (HFrEF) according to clinical trial data. Treatment of heart failure with sodium-glucose transporter-2 inhibitors (SGLT2i) has recently made significant strides [1]. Even in patients with HFrEF, LV diastolic dysfunction was a separate predictor of outcome [2]. It is essential to identify structural abnormalities using echocardiography since they have been linked to prognosis in HF and DM patients [3]. Both diabetic and non-diabetes patients with HF have had their risk of death and hospital readmission decreased by SGLT2is, according to large-scale randomised studies and meta-analyses [4]. These are part of the global guidelines for the treatment of heart failure (HF) at the intermediate assessment level [5]. Some theories suggest that SGLT2is exerts its cardioprotective effects by reversing cardiac remodelling [6] and restoring systolic and diastolic function [7].Some theories suggest that SGLT2is exerts its cardioprotective effects by reversing cardiac remodelling and restoring systolic and diastolic function
Keywords
heart failure; sodium-glucose transporter-2 inhibitor; diastolic function
Statistics
Article View: 255
PDF Download: 258